Current Status and Perspective on the Use of Viral-Based Vectors in Eukaryotic Microalgae

Omayra C. Bolaños-Martínez 1,2, Ganesan Mahendran 1,2, Sergio Rosales-Mendoza 3,4 and Sornkanok Vimolmangkang 1,2,*

1 Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand; omayra.cbm@hotmail.com (O.C.B.-M.); mahendran0007@gmail.com (G.M.)
2 Center of Excellence in Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, Thailand
3 Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosí 78210, Mexico; rosales.s@uaslp.mx
4 Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona 550, Lomas 2a Sección, San Luis Potosí 78210, Mexico
* Correspondence: sornkanok.v@pharm.chula.ac.th; Tel.: +662-218-8358

Abstract: During the last two decades, microalgae have attracted increasing interest, both commercially and scientifically. Commercial potential involves utilizing valuable natural compounds, including carotenoids, polysaccharides, and polyunsaturated fatty acids, which are widely applicable in food, biofuel, and pharmaceutical industries. Conversely, scientific potential focuses on bioreactors for producing recombinant proteins and developing viable technologies to significantly increase the yield and harvest periods. Here, viral-based vectors and transient expression strategies have significantly contributed to improving plant biotechnology. We present an updated outlook covering microalgal biotechnology for pharmaceutical application, transformation techniques for generating recombinant proteins, and genetic engineering tactics for viral-based vector construction. Challenges in industrial application are also discussed.

Keywords: biopharmaceuticals; recombinant proteins; transient expression; viral vectors

1. Introduction

Microalgae are unicellular microorganisms found in marine and freshwater ecosystems over a wide range, from very small (a few micron) to large (a few hundreds of microns). They can rapidly produce biomass from solar energy, CO2, and nutrients, such as nitrogen, sulfur, and phosphorous. Simple maintenance and cultivation in artificial environments offer a profitable platform to produce and extract bioactive compounds compared with other bioresources. Here, microalgae produce various metabolites with applications in pharmaceutical, cosmetic, bioenergy, and food/feed industries [1,2]. Various microalgae-derived products for food and feed have already been commercialized by different companies worldwide, including A4F-Algae 4 Future (Portugal), Blue Biotech (Germany), DIC Lifetec (Japan), E.I.D Parry (India), Ocean Nutrition (Canada), Phycom (Netherlands), Chlorella Co. (Taiwan), and Solazyme, Inc. (San Francisco), all of which used their bioactive compounds as colorants, additives, or supplements [3].

Biopharmaceuticals are complex molecules of biological origin used to diagnose, prevent, treat, and cure diseases or conditions in human beings and animals. According to their biological structure, biopharmaceuticals can be classified into amino acids, nucleic acids, and vaccines. In biopharmaceutical terms, these molecules are specifically produced under biotechnological processes based on genetically engineered organisms used as an expression host [4]. The main organisms used here are bacteria, yeast, mammalian cells, and insect cells, with each system having their own advantages as well as limitations [5–8].
Recently, microalgae have attracted increasing scientific interest due to their versatile growth and functional metabolic properties, as well as their biopharmaceutical production. Microalgae possess distinct attributes that have attracted the attention of biotechnologists, who have developed advanced genetic and molecular tools to leverage microalgae as green bioreactors to produce biopharmaceuticals. These attributes include their ability to grow and culture under heterotrophic, autotrophic, and mixotrophic conditions, the capacity to realize post-translational modifications and proper protein maturation, and the distinction of some microalgae species as “Generally Recognized as Safe” by the Food and Drug Administration (FDA). This status is conferred to any substance, chemical, or a whole organism that is safe for human consumption, owing to the absence of pathogens, microorganism, or related endotoxins. Mostly heterotrophic microalgae are FDA-approved for biotechnological applications due to their large-scale growing capacity and high cell density compared with other organisms [9,10].

To increase the yield and accelerate time to obtain and improve biopharmaceutical quality, microalgae biotechnology uses various expression methods and genetic and molecular biology strategies. These methods include stable nuclear and chloroplast expression and, in recent years, transient expression using viral-based vectors that allow high protein accumulation in a short period of time. However, the method using *Agrobacterium tumefaciens* transformation makes oral formulations of algal biomass unusable due to residual bacteria. Conversely, viral vectors for this purpose are limited and are mainly designed using elements derived from plant viruses. We present an updated outlook covering microalgal biotechnology for pharmaceutical applications, transformation techniques for obtaining recombinant proteins, and genetic engineering tactics for viral-based vectors construction (Figure 1). Finally, we discuss the potential challenges in industrial application.

Figure 1. Overview of microalgal biotechnology for biopharmaceutical application. The essential components are from the vector design and selection of gene interests, microalgal hosts, and methods of transformation to finally obtain either bioactive metabolites or biopharmaceuticals. (A). Plasmid construction and transfer to *Agrobacterium*. (B). Selection of microalgae for genetic transformation.
(C). Method to transfer plasmid DNA using electroporation. (D). Introduction to target gene through the Agrobacterium-mediated method. (E). Stepwise protocol for the transfer of genes. (F). Traditional algae transformation method (glass beads). (G). Transformation methods (direct or Agrobacterium mediated) and integration into algae cell. (H). Stages of development for large-scale production of valuable biopharmaceuticals.

2. Genetic Engineering Transformation Methods for Biopharmaceutical Production of Microalgae

During the last 20 years, 40 different microalgae species genetic engineering methods have been developed [11,12]. Chlamydomonas reinhardtii, Dunaliella salina, Volvox carteri, Haematococcus pluvialis, and Phaeodactylum tricornutum are widely used microalgae for transforming foreign transgene expression studies, as well as biopharmaceutical protein production [13–17]. Here, microalgae genomes, such as nuclear, chloroplast, and mitochondrial transformation protocols, have been explored. In microalgae, four traditional methods are widely used to deliver foreign genes into microalgal genomes, including agitation with glass beads [18], particle bombardment [19], electroporation [20], and Agrobacterium-mediated transformation [21–25]. Of these methods, glass beads and Agrobacterium do not require any specialized apparatus, are less labor-intensive, and are relatively fast [18,26]. Additionally, bacterial conjugation as well as natural and liposome-mediated transformation also have been employed, each of these exhibiting their own advantages and drawbacks. The most notable disadvantages presented for some methods include the need for optimizing the transformation conditions, the low efficiency, and the high cost of the equipment or interface used [27].

Using the agitation method, transformation involves agitating wall-deficient cells/protoplasts of microalgae with foreign genes, glass beads, and polyethylene glycol (surfactant) [28–30]. This method can be used for both nuclear and chloroplast transformation. Furthermore, studies show cell wall-removed protoplasts are sufficient for gene transformation in Chlorella ellipsosidea [31]. Glass bead agitation has also been reported in chloroplast genetic engineering in C. reinhardtii using agitation of DNA/cell suspensions with glass beads [32]. The glass bead method also includes low transformation efficiencies due to thick cell walls, agitation duration, velocity, and surfactant concentration [12,33–35]. Table 1 presents and compares the limitations of different transformation methods.

| Method       | Advantage                                           | Disadvantage                                      | Integration Site | Transformation Efficiency | Microalgae Species                  | Reference |
|--------------|-----------------------------------------------------|---------------------------------------------------|------------------|--------------------------|-------------------------------------|-----------|
| Glass beads  | Simple, controllability, high cell-survival rate, affordable, and minimal physical damage to cells | Cell wall removal and low transformation efficiency | Nucleus          | ~10^3 µg DNA\(^{-1}\)   | Chlamydomonas reinhardtii, Dunaliella salina, Platymonas subcordiformis | [18]      |
|              |                                                     |                                                   |                   | NR                       |                                     | [36]      |
|              |                                                     |                                                   |                   | NR                       |                                     | [37]      |
|              |                                                     |                                                   |                   | 6 × 10^7 per µg of DNA, 2.5 × 10^4 per µg of DNA, 1.1 × 10^7 per µg of DNA | Chlamydomonas reinhardtii, Nannochloropsis linnetica, Chlamydomonas reinhardtii, Dunaliella salina, Scenedesmus obliquus, Monoraphidium neglectum, Chlorella pyrenoidosa, Nannochloropsis oculata | [20] [39] [40] |
| Electroporation | Simple, affordable equipment, and high transformation efficiency | Transformation frequency affected by higher pulse strength and length, medium composition, temperature and membrane characteristics | Nucleus          |                         |                                     |           |
The **Agrobacterium**-based transformation method has previously been applied to *C. reinhardtii* [23,50,58], *H. pluvialis* [22,59], *Chlorella vulgaris* [60], *Parachlorella kessleri* [61], *Dunaliella bardawil* [46,47], *D. salina* [62], *Euglena gracilis* [63], *Cenedesmus almeriensis* [64], and *Dictyosphaerium pulchellum* [65]. According to Bashir et al. (2018), efficiency transformation using the Agrobacterium-based method was 50-fold higher that the glass bead method. However, different transformation efficiencies have been reported with Agrobacterium-based protocols [23,50,58]. Factors such as co-cultivation temperature, optical density, infection time, pre-culture duration, and acetosyringone concentration can substantially affect transformation efficiency [47,60]. In a study by Kumar et al. (2004), the Agrobacterium-based method performed equally as well as electroporation for stable integration into *Parachlorella kessleri* [61].

Electroporation is the most common and effective method for performing high-intensity electric pulses across the microalgae cell membranes to allow exogenous DNA to pass through cells [66–68]. This method has been reported in *C. reinhardtii* [20,38,39], *Nannochloropsis limnetica* [40], *D. salina* [41], *Scenedesmus obliquus* [42], *Monoraphidium neglectum* [43], *Chlorella pyrenoidosa* [44], *C. vulgaris* [69], *Chlorella zofingiensis* [70], and *Nanochloropsis oculata* [45]. Advantages include a rapid protocol, low labor, and high speed. Electroporation has been also been reported with transformation efficiencies up to 100-fold over agitation [12]. However, transformation efficiencies may be affected by electric-strength, pulse, and cell wall complexity [20,71,72].

Particle bombardment is an early and highly reproducible transformation method due to its ability to deliver genes into the nucleus, mitochondria, and chloroplast genomes without disturbing the cell walls [19,49,73,74]. This method is based on a DNA-coated ejection device with tungsten or gold metal particles that can detect target cells. Successful transformation using particle bombardment have previously been reported for *C. reinhardtii* [9,49–51,75,76], *D. salina* [77], *Haematococcus pluvialis* [59], *V. carteri* [48], *P. tricho-
Among these techniques, the particle gun method is the most efficient for direct DNA delivery into cells. Generally, the gene gun method shows high transformation efficiency; however, this method is costly. Both particle bombardment and electroporation can be applied to transfer not only endogenous DNA but also proteins into microalgae cells. The most important application introduced Cas9 protein-gRNA ribonucleoproteins (RNPs) into microalgae, namely, into *C. reinhardtii*, *P. tricornutum*, and *Tetraselmis* sp. cells, for DNA-free genome editing [80–83].

In addition to the aforementioned methods used to introduce foreign DNA into microalgae cells, other transformation methods are also available. Hawkins and Nakamura (1999) showed *Chlorella* sp. protoplast cells and plasmids can be generated by mixing with polyethylene glycol and dimethyl sulfoxide for human growth hormone gene transformation [84]. Similarly, Liu et al. (2013) described novel, simple, reliable, and cost-effective transformation of *C. ellipsoidea* protoplast cells by mixing foreign DNA with PNC solution (NaCl, CaCl₂, and 40% PEG 4000) [71]. Other methods include stable nuclear transformation systems for *Pleurochrysis carterae* using polyethylene glycol (PEG)-mediated transfer of hygromycin B-resistance genes [85]. Recent reports present genetic transformation of microalgae by bacterial conjugation [86,87] and gene injection [88]. In addition to these techniques, other emerging methods, such as cell-penetrating peptides, nanoparticles, metal–organic frameworks, and liposomes, have not yet been demonstrated in microalgae [12,89–91].

3. Microalgae Nuclear and Chloroplast-Based Expression

Microalgae contain nuclear, mitochondrial, and chloroplast genomes, each of which have their own transcription, translation, and post-translation properties [92]. Nuclear expression in microalgae offers numerous benefits, such as targeting recombinant protein expression in specific organelles, protein glycosylation, post-translational modification, and secretion [93]. In nuclear-based expression, the position of an exogenous gene into a microalgal genome occurs as a random insertion and usually transgenic cells are selected via phenotypic variation or antibiotic resistance. Generally, this approach results in low yields. Although the reasons for this phenomenon are not completely understood, possible explanations could be attributed to the RNA-silencing process, transcript instability, positional effects of transgenes, and an inaccessible chromatin structure [94].

Using chloroplasts to express foreign genes has become a promising alternative to the nuclear genome. Microalgae chloroplasts serve as the main cell factory for synthesizing several metabolic pathway enzymes and appropriate transformation objects for producing isoprenoids, carbohydrates, lipid, carotenoids, pigments, fatty acids, and proteins [95,96]. Further, this organelle lacks a gene-silencing mechanism and may be used to protect proteins from degradation and involve some post-translation modifications, such as phosphorylation. These multiple functions in a single cell organelle are the most important traits for its heterologous gene expression in microalgae [97,98]. For delivery, the foreign gene must pass through several membranes, which represent a greater challenge. The preferred method to achieve this goal is particle bombardment. In particular, *C. reinhardtii* has been described in numerous transformation studies for producing foreign proteins due to the chloroplast genome being fully sequenced and offering a unique advantage in the transformation system [99]. Further, various transformation methods have been reported for *C. reinhardtii* chloroplasts, among which are the marker-free chloroplast transformation system [100] and glass bead agitation using cell wall-deficient cells [28–30]. Finally, a chloroplast transformation system based on electroporation has also been developed for *Phaeodactylum tricornutum* [101].

4. Algal Biotechnology in Pharmaceutical Applications

In biochemistry, metabolites are defined as small molecules of <1.5 kilodaltons (KDa) that act as intermediates or end products in cellular metabolism and are classified as pri-
mary and secondary. Primary metabolites are directly involved in growth, development, and reproduction, whereas secondary are not implicated in these processes but offer an important ecological function and are typically linked to specific environmental conditions or developmental stages [102]. In microalgae, diverse bioactive metabolites have been studied for their antifungal, anticancer, antibacterial, and immunosuppressive properties [103–107].

Further, bioactive compounds obtained from microalgae, such as β-carotene, polyunsaturated fatty acids (Omega-3), chlorasterol, phycocyanin, lutein, astaxanthin, canthaxanthin, fucoxanthin, zeaxanthin, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), can be applied as nutraceuticals, food additives, or in the cosmetics industry. Amino acids, such as tryptophan, lysine, leucine and arginine, vitamins B and E, essential minerals, and carbohydrates, are used in human and animal nutrition. Further, metabolites obtained from microalgae can be used in biofertilizer production as a source of nitrogen- and phosphorous-rich biomass residues as feedstock and in the bioenergy industry as bulk oil and biomass residue feedstock for jet fuel, biodiesel, bioethanol, biogas, biochar, and biohydrogen production. Furthermore, some microalgae strains can be used in wastewater treatment by reducing the amount of nitrogen, phosphate, and chemical oxygen demand, as well as removing heavy metals (copper (Cu), iron (Fe), manganese (Mn), and zinc (Zn)) and pharmaceutical pollutants (triclosan and hormones (17β-estradiol and 17α-ethinylestradiol) [108–113]. Interestingly, potential industrial applications and commercialization of microalgae-derived biomass and bioactive compounds in the food industry has recently been explored by Camacho et al. (2019). This analysis introduced the potential for formulation as prebiotics or as part of functional food/feed for human and animal consumption. Further, various industries can commercialize products, including phycocyanin, lutein, β-carotene, astaxanthin, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (ω-3), derived from microalgae to be used as food colorants or supplements [3]. Currently, different species of microalgae have been used in the food/feed industry, such as *Porphyridium cruentum*, *Pavlova salina*, *Tisochrysis lutea*, *Chaetoceros muelleri*, *Nannochloropsis* spp., *Skeletonema* spp., *Thalassiosira pseudonana*, *Schizochytrium* sp., and *Cryptochroodium cohnii*, and wastewater bioremediation, including *Scenedesmus obliquus*, *Francea* sp., *Ankistrodesmus* sp., *Tetraedron* sp., *Chlorella* sp., and *Mesotaenium* sp. [114].

Conversely, using single-cell engineering microalgae as a green factory to produce biopharmaceuticals includes recombinant expression of numerous antigenic proteins that act as human and animal vaccine candidates against viral or bacterial diseases and parasitic infections. Among these candidates, expression of viral epitopes from Zika virus [115], avian influenza [116], human papillomavirus [117], hepatitis B [41], and human immunodeficiency virus (HIV) [118], as well bacterial proteins from *Staphylococcus aureus* [76] and *Histophilus somni* [119], are well studied. Regarding parasitic infections, proteins from *Plasmodium falciparum* that cause malaria are also expressed in microalgae [120,121]. Furthermore, microalgae are also used to produce monoclonal antibodies, hormones, cytokines, growth factors, immunotoxins, and proteins to prevent non-communicable diseases [122–125]. A detailed recompilation of biopharmaceuticals produced in microalgae are summarized in Table 2. In addition, these recombinant microalgae cells can be utilized as an effective oral drug delivery platform formulated as pills, tablets, or freeze-dried cells [9]. A study by Kwon et al. (2019) demonstrated that the green fluorescent protein (GFP) expressed in chloroplasts of *C. reinhardtii* remained intact after biomass lyophilization [126].
Table 2. Production of recombinant biopharmaceuticals proteins in microalgae.

| Microalga Strain | Transformation Method | Integration Site | Protein Expressed | Yields Obtained | Application | Reference |
|------------------|-----------------------|------------------|-------------------|-----------------|-------------|-----------|
| *Dunaliella salina* | Lithium acetate/PEG   | Nucleus          | SKTI              | 0.68% TSP       | Antivirus and anticancer | [57]      |
|                  | *Agrobacterium*-mediated transformation | | H5HA              | 225 µg TSP/2g    | Avian influenza | [127]     |
|                  | Electroporation       |                  | HBsAg            | 3.11 ± 0.50 ng/mg | Hepatitis B | [41]      |
|                  | Glass beads           |                  | VP28             | 3.04 ± 0.26 ng/mg and 78 µg/100 mL culture | White spot syndrome in crayfish | [128] |
|                  | Biolistics            | Chloroplast      | sTRAIL           | 0.67% TSP       | Tumor cells and virus-infected cells | [129] |
|                  | *Agrobacterium*-mediated transformation | Nucleus         | HBcAgII          | 0.05% TSP       | Hypertension | [130]     |
|                  |                       |                  | IFN-α2a          | NA              | Immunity    | [131]     |
|                  |                       |                  | RBD              | 1.61 µg/g FWB   | COVID-19    | [35]      |
|                  |                       |                  | IF               | NA              | Autoimmune disease | [139] |
|                  |                       |                  | hVEGF-165        | 0.2 to 1.0 mg of protein/mg | Tissue hypoxia, wound healing | [120] |
|                  |                       |                  | hPDGF-B, and hSDF-1 | 0.06% TSP, 0.003% TSP, 0.0006% TSP | Tissue hypoxia, wound healing | [135] |
|                  |                       |                  | P24, CpP24, CrP24, P24w | 0.25% TSP | AISD | [118] |
|                  |                       |                  | hEGF             | 0.2%–0.25% TSP (40 mg/L) | hEGF deficiency | [136] |
|                  |                       |                  | Endolysin (Cpl-1 and Pal) | ~1.3 mg/g ADW | Streptococcus pneumoniae infection | [137] |
|                  |                       |                  | ALFPm3           | 0.35% TSP       | Anti-bacteria, anticancer, and antiviral activity | [138] |
|                  |                       |                  | IF               | NA              | Autoimmune disease | [139] |

*Chlamydomonas reinhardtii*

| Transformation Method | Integration Site | Protein Expressed | Yields Obtained | Application |
|-----------------------|------------------|-------------------|-----------------|-------------|
| Electroporation       | Chloroplast      | WSSV VP28         | NA              | White spot disease in shrimp | [132] |
|                       |                  | hGH               | 0.5 mg hGH/L    | Growth Hormone | [32]      |
|                       |                  | dsRNA             | NA              | Yellow head virus infection in shrimp | [133] |
|                       |                  | ctxB-pfs25        | 0.09% TSP and 20 µg/mL | | Cancer | [117] |
|                       |                  | pfs25 and pfs28   | Pfs25 (0.5%) and Pfs28 (0.2%) TSP | Malaria | [134] |
|                       |                  | c.r.pfs48/45      | NR              | | | [75] |
|                       | Nucleus          | AMA1/MSP1-GBSS    | 0.2 to 1.0 mg of protein/mg | | | [120] |
|                       |                  | hVEGF-165         | 0.06% TSP, 0.003% TSP, 0.0006% TSP | Tissue hypoxia, wound healing | [135] |
|                       |                  | hPDGF-B, and hSDF-1 | 0.06% TSP, 0.003% TSP, 0.0006% TSP | Tissue hypoxia, wound healing | [135] |
Table 2. Cont.

| Microalgae Strain | Transformation Method | Integration Site | Protein Expressed | Yields Obtained | Application | Reference |
|-------------------|-----------------------|------------------|-------------------|-----------------|-------------|-----------|
| Chlamydomonas reinhardtii | Biolistics | Chloroplast | αCD22 | 0.7% TSP | Cancer | [124] |
| | 83K7C | | 100 mg/1 g of DAB | Anthrax | [140] |
| | HSV8 scfv | | 0.5% TSP | Herpes simplex virus | [141] |
| | HSV8-lsc | | >1% TSP | Herpes simplex virus | [142] |
| | M-SAA | | 0.25% TSP | Protection against intestinal bacterial and viral infections in newborns | [143] |
| | apcA and apcB | | 2–3% TSP | Inhibit the S-180 carcinoma in mice | [144] |
| | hMT-2 | | NA | UV-B effects | [145] |
| | CTB:p210 | | 60 µg/g of FWB | Atherosclerosis | [146] |
| | Ara h 1 and Ara h 2 | | NA | Peanut allergy | [147] |
| | Bet v 1.0101 | | 0.01 and 0.04% TSP | Allergy | [148] |
| | IL-2 and PfCelTOS | | 1.5% TSP | Malaria | [121] |
| | IFN-β1 | | NA | Multiple sclerosis | [149] |
| | VEGF | | 0.1% TSP | Depression and pulmonary arteries | [149] |
| | HMGB1 | | 1% TSP | Response of the brain to neural injury and wound healing | [149] |
| | CelK1 | | 0.003% TSP | Bioethanol and biogas production | [150] |
| Schizochytrium sp | Biolistics | Nucleus | huBuChE | 0.4% TSP | Pesticide poisonings | [151] |
| Schizochytrium sp. ATCC 20888 | Biobalistic | Nucleus | GP1 and LTB | 1.25 mg/g FWB (6 mg/L of culture) | Ebola | [79] |
| | Electroporation | Nucleus | Mytichitin-A | 0.28% TSP | Growth inhibition of fungi, viruses, parasites, and bacteria | [152] |
| | | | ToAMP4 | 0.32% TSP | Antimicrobial | [153] |
| | | | hLF | 1.82% TSP | Antibacterial | [154] |
| | | | HER-2, MUC1, MAM-A, and WT1 | 637 µg/g FWB | Breast cancer | [155] |
| | | | ZK1, ZK2, ZK3, and LTB | 365 µg/g FWB | Zika disease | [115] |
| | | | LTB-RAGE | 380 µg/g FWB | Alzheimer disease | [156] |
Table 2. Cont.

| Microalgae Strain | Transformation Method | Integration Site | Protein Expressed | Yields Obtained | Application | Reference |
|-------------------|-----------------------|------------------|-------------------|-----------------|-------------|-----------|
| *Chlorella vulgaris* | Agrobacterium-mediated transformation | Nucleus | RBD | 1.14 µg/g FWB | COVID-19 | [35] |
|                      |                       |                  | bFGF | 1.61 ng/g FWB | Growth factor |           |
| *Chlorella sp*      | Electroporation       | Nucleus          | Scygonadin and hepcidin | NA | Antibacterial | [157] |
| *Chlorella sorokiniana* | PEG | Nucleus | hGH | 200–600 ng/mL | Cell regeneration/hGH deficiency | [84] |
| ATCC-22521) or *Chlorella vulgaris C-27* | Biobalistic | Chloroplast | fGH | 420 µg fGH protein/L | Growth hormone | [123] |
| *Chlorella ellipsoidea* | Biobalistic | Chloroplast | Xylanase, α-galactosidases, Phytase, phosphate anhydrolase, and β-mannanase | NA | | |
| *Dunaliella tertiolecta and C. reinhardtii* | Biobalistic | Plastids | | | Animal feeds and biofuel production | [158] |
| *Haematococcus pluvialis* | Biobalistic | Chloroplast | Piscidi-4 | NA | Antimicrobial | [159] |

PEG: Polyethylene glycol; SKTI: Soybean Kunitz trypsin inhibitor; TSP: Total soluble protein; HSHA: Hemagglutinin-Influenza A virus; TRIM: Total soluble protein, HBsAg: Hepatitis B surface antigen; HBeAgII: Angiotensin II fusion to hepatitis B virus (HBeAg); HPV16 E7: Human papillomavirus 16 E7 protein, ctsB-pfs25: Plasmodium falciparum surface protein (Pfs25) fused to cholera toxin (CtxB); pfs25 and pfs28: Plasmodium falciparum surface protein 25 and 28; c.pfs48/45: Plasmodium falciparum surface protein 48/45; AMA1/MSPI-GBSS: Apical major antigen or major surface protein fused to granule bound starch synthase; CTB-D2: fibronectin-binding domain D2, fused to the cholera toxin B subunit protein; hGAD65: Human glutamic acid decarboxylase; CSFV E2: classical swine fever virus structural protein E2; αCD22: Immunotoxin protein; 83K7C: Human IgG1 monoclonal antibody 83K7C against the PA83 anthrax antigen; DAB: dry algal biomass; HSV8 scfv: single-chain variable regions antibody against Herpes simplex virus glycoprotein D; hBuChE: A fusion protein containing luciferase and the human butyrylcholinesterase; AISD: Acquired immunodeficiency syndrome; FWB: Fresh weight biomass; IL-2 and PCEITOS: PCEITOS fused to human interleukin-2; sTRAIL: Tumor factor-related apoptosis inducing ligand; IFN-β1: Human interferon-β1; VEGF: Human vascular endothelial growth factor; HMBG1: High mobility group protein B1; hEGF: Human epidermal growth factor; ALFPm3: Anti-Lipopolysaccharide factor isoform 3; ColK1: Bacterial endoglucanase (CelK1, Glycohydrolase, family 5) enzyme; hGH: human growth hormone, M-SAA: Bovine mammary-associated amyloid; HMT-2: Metallothionein-2; IFN-α2a: Human interferon-α; IF: Human protein intrinsic factor; WSSV VP28: White spot syndrome virus protein; ToAMP4: Taraxacum officinale antimicrobial peptide 4; hLF: Human lactoferrin; HER-2 Human Epidermal Growth Factor Receptor-2; MUC1: Mucin-like glycoprotein 1; WT1: Wilm’s Tumor Antigen; MAM-A: Mammaglobin-A; LTB:RAGE: Receptor of Advanced Glycation End products fused to *E. coli* heat-labile enterotoxin B subunit; GP1: Complex viral proteins from Zaire ebolavirus; HA: Recombinant hemagglutinin from A/Puerto Rico/8/34 (H1N1) influenza virus; fGH: flounder growth hormone.

5. Viral-Based Expression Vectors for Recombinant Protein, Vaccine, and Biopharmaceutical Production

Currently, biotechnology and genetic engineering is harnessing numerous viruses or their component parts to produce heterologous proteins for human and animal use. Given the expression of epitopes from influenza A virus can be fused with the hepatitis B core antigen in *Nicotiana benthamiana* plants, generation of virus-like particles (VLPs) in insect cells for the human papilloma virus as a vaccine-delivery vehicle for genetic material can generate an immune response in the human body, as recently developed for a COVID-19 vaccine [160–162]. Furthermore, polymerases and reverse-transcriptases from viral origins, in addition to elements such as transcriptional promoters, terminators, silencing suppressors, and internal ribosomal entry sites, form part of a molecular toolbox for genetic engineers, biologists, and biotechnologists.
The common approach for generating viral-based expression vectors involves inserting a determinate viral genome sequence into an expression vector downstream of a cell-type-specific promoter. The coding sequence of a heterologous gene is then inserted into the viral genome sequence as part of a viral polyprotein or downstream to a subgenomic promoter. The construct is then transferred to host cells for transcription and subsequent translation processes by host molecular machinery [163]. During the last decade, the design, generation, and use of viral-based expression vectors for producing heterologous proteins have gained increasing scientific interest, mainly in the plant biotechnology field. To achieve this goal, expression strategies have focused on RNA and DNA plant viruses, of which tobamovirus, comovirus, potexvirus, and geminivirus are the most exploited genera.

Developing and applying this approach has followed an interesting path. First, by creating first-generation expression vectors or full virus strategies based on expression of the gene of interest (GO), this approach has also produced its own viral genes and subsequent translation as an individual antigenic or fusion protein on the C-terminal of the capsid protein (CP). Using these vectors, several immunogens have been produced, reaching up to 10% of the total soluble protein (TSP) in Nicotiana benthamiana plants. However, stability is negatively related to insert size, hence the proteins larger than 30 KDa are poorly expressed in a chimeric CP form and epitopes should be 25 amino acids at maximum length [164–166]. These drawbacks slowed the development of second-generation viral vectors, whereby using a full virus was replaced with a deconstructed virus genome containing essential elements for replication and non-viral sequence integration to accomplish other functions, such as replication formation using T-DNA delivered via Agrobacterium tumefaciens. Using Agrobacterium for DNA delivery offers considerable advantages given the efficient transfer capacity by infiltration of plant leaves. Plants species using this approach include spinach, sunflower, red beetroot, and N. benthamiana, presenting maximum yields up to 50% of TSP in a 4–5 day period where the size of the GO can be up to 2 Kb and proteins of 80 KDa can be produced [167–169].

Special attention should be directed toward DNA virus-based vectors, specifically those applying elements from geminivirus, a twinned icosahedral virus with a single-strand DNA (ssDNA) arranged in one (monopartite) or two components (bipartite) encoding proteins essential for the replication process, pathogenicity, suppression of plant gene silencing, and intercellular and long-distance movement of the virus [170,171]. In general, these vectors are based on a transient expression system, the advantages of which include rapid product expression, high production rate, flexibility, and scalability. A geminivirus engineered for biopharmaceuticals is Bean Yellow Dwarf Virus (BeYDV), which has been modified to leverage its Rep protein under independent promoter control. With this strategy, diverse BeYDV-based expression vectors have been engineered and an assortment of antigens and monoclonal antibodies have been generated [172–174]. For microalgae, the geminiviral vector pBYR2e was used for expression of the receptor-binding domain (RBD) from SARS-CoV-2 and fibroblast growth factor (bFGF) in two freshwater microalgal species. Yields reached up to 1.61 µg/g and 1.14 µg/g for RBD when expressed in C. reinhardtii and C. vulgaris, respectively [35]. Conversely, Berndt et al. (2021) reported expression of RBD-fused GFP in C. reinhardtii. Interestingly, the protein targeted three different cellular localizations: (i) in the endoplasmic reticulum–Golgi pathway; (ii) secreted out of the cell into the culture media; and (iii) directed to the chloroplasts. In the latter, although under higher expression, the protein appeared to be truncated by ~5 kDa at the amine end, whereas the end targeted to the ER was produced with the expected size and correct amino acid sequence. For obtaining proteins, the transgene was placed into the pBR9 and pOpt vectors; in particular, the pBR9 vector containing the sh ble zeocin resistance selection marker with a food and mouth disease virus (FMDV) 2A self-cleaving sequence placed between the coding sequences, resulted in accumulation of two separate proteins [175].

Another geminivirus-based vector, named Algevir, has been developed with diverse antigenic proteins and epitopes expressed in the marine microalgae Schizochytrium sp., which was engineered using the Rep protein and origin of replication (Ori) from the bego-
movirus *Ageratum enation* to produce and replicate circular DNA carrying the GO and AlcR gene, as well as the AlcA promoter from *Aspergillus nidulans* to obtain ethanol-induced expression. This innovative system has produced viral and bacterial proteins at a maximum level production of 1.25 mg/g fresh biomass for GP1 from *Zaire ebolavirus* [79]. Table 3 shows the viral-based vectors used for biopharmaceutical production in microalgae. However, yields produced in microalgae with a nuclear approach and using viral-based vectors do not fully outcompete those produced in chloroplasts whereby targets allow production of 3.28 mg/L of culture medium [176]. The strategy based on protein production in this organelle requires a long time and construction of detailed vectors containing specific sequences for integration by homologous recombination. Here, optimizing viral-based vectors is needed to increase the protein yield and improve stability, which requires transient expression as a primary approach given that some transgene products may become toxic for host cells, leading to very low yields under stably transformed lines. Alternatively, microalgae viruses can be naturally used to drive gene expression at different infection stages and viral elements can be explored throughout the design process of novel viral-based vectors or when improving current models. Updating the functions of viral genes and the genome composition is an important requirement for executing a rational design in which regulatory elements, such as promoters, terminators, or replication proteins, help reach strong GO expression. Finally, exploring the possibility of directly purifying recombinant proteins using elements from lytic viruses presents an alternative approach [177].

**Table 3.** Virus-based vectors used for biopharmaceutical production.

| Microalgae Host     | Type of Transformation | Name      | Viral Elements                                      | Protein Expressed                                      | References          |
|---------------------|------------------------|-----------|----------------------------------------------------|-------------------------------------------------------|---------------------|
| *Schizochytrium* sp. | Transient nuclear/Inducible expression | Algevir   | *Cauliflower mosaic virus*: 35S promoter            | The GP1 from *Zaire ebolavirus* and LTB                 | [79,115,155,156]    |
|                     |                        |           | 35S terminator                                      | RAGE (23–54 amino acids)                               |                     |
|                     |                        |           | *Ageratum enation virus*: Replication protein “Rep”| The ZK1, ZK2, ZK3 from the E protein from Zika virus    |                     |
|                     |                        |           | Origin of replication “Ori”                         | fused to LTB                                           |                     |
|                     |                        |           |                                                    | The multiepitope protein BCB comprised epitopes from   |                     |
|                     |                        |           |                                                    | HER-2, MUC1, WT1, MAM-A fused to LTB                   |                     |
| *Chlamydomonas reinhardtii* |                        |           |                                                    |                                                       |                     |
| *Chlorella vulgaris* | Transient nuclear      | pBYR2e    | *Cauliflower mosaic virus*: 35S promoter            | The RBD from SARS-CoV-2                                 | [35]                |
|                     |                        |           | *Tomato bushy stunt virus*: RNA silencing suppressor P19 |                                                       |                     |
|                     |                        |           | *Bean Yellow Dwarf Virus*: Short intergenic region SIR|                                                       |                     |
|                     |                        |           | *Long intergenic region LIR C1/C2*: Replication protein A |                                                       |                     |
|                     |                        |           | *Tobacco mosaic virus*: 5’ untranslabeled region    |                                                       |                     |
|                     |                        |           |                                                    |                                                       |                     |

LTB: Bacterial toxin B subunit of the heat-labile *E. coli* enterotoxin; RAGE: Receptor of Advanced Glycation End products; ZK1: amino acids LDKQSDTQVYVCKRTLVD; ZK2: amino acids FSDLYYLM; ZK3: amino acids LKGSYSLCLATAFITFK; HER-2 Human Epidermal Growth Factor Receptor-2; MUC1: Mucin-like glycoprotein 1; WT1: Wilms’ Tumor Antigen; MAM-A: Mammaglobin-A; RBD: Receptor Binding Domain; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; bFGF: Fibroblast Growth Factor.

### 6. Design of a Viral-Based Vector for Microalgae Use

In the virosphere, many species are capable of infecting microalgae. In addition to triggering high mortality rates, such species can reprogram host metabolism, including photosynthesis and important cycling processes, such as central carbon metabolism, phosphorus, nitrogen, and sulfur [178].

To date, a total 63 virus that infect eukaryotic microalgae have been isolated and cultured in the laboratory, whereby 50.79% contain dsDNA as genomic material, 15.8% ssDNA, 1.58% dsRNA, and 22.2% ssRNA, whereas 7.93% have not yet been classified [163,179].
Recently, a list of 10 isolated and characterized viruses was published by Sandaa et al. (2022) [180]. These viruses can infect marine haptophytes species. Here, a rational design of a microalgal-specific viral vector to achieve higher protein yields, using viral elements that naturally infect microalgae, could be a promising strategy.

In a study published by Kadono et al. (2015) [181], a set of five potential promoter regions located upstream of the replication-associated protein (VP3) or structural protein (VP2), coding genes for three marine diatom-infecting viruses (DIVs), were evaluated and compared in the Pennales diatom *Phaeodactylum tricornutum* as a heterologous host (Table 4). The gene-encoding fucoxanthin chlorophyll a/c-binding protein (fcp) was used as an endogenous promoter and eGFP as a protein reporter. In addition, the extrinsic promoter, such as *Cauliflower mosaic virus* 35S (CaMV35S), cytomegalovirus (CMV), and nopaline synthase gene (nos) promoter, were also used. The results show the novel promoter ClIP1 mediated significantly higher transcription and translation rates according to mRNA transcripts and flow cytometry analysis, respectively. Further, the abundance of eGFP mRNA transcripts in the stationary phase were higher than those found in the log phase under both low and standard nutrient culture conditions.

### Table 4. Molecular elements from viruses infecting microalgae tested for the expression of recombinant proteins.

| Viral Genomic Element | Name | Viral Source | Size (bp) | Type of Expression | Transformation Method | Protein Expressed | Heterologous Host | Reference |
|-----------------------|------|--------------|-----------|--------------------|----------------------|-------------------|-------------------|----------|
| Promoters             |      |              |           |                    |                      |                   |                   |          |
| ClorDNAV              | C1P1 | ClorDNAV     | 502       | Stable             | Bioblastic           | eGFP              | *Phaeodactylum tricornutum* | [181]    |
|                       | C1P2 |              | 474       |                    | Electroporation      | Sh ble            | Chlamydomonas reinhardtii |          |
| CdebDNAV              | C2P1 | CdebDNAV     | 477       | Stable             | Bioblastic           | eGFP              | *Phaeodactylum tricornutum* |          |
| TnitDNAV              | TnP1 | TnitDNAV     | 424       |                    |                      |                   |                   |          |
|                       | TnP2 |              | 424       |                    |                      |                   |                   |          |

ClorDNAV: Chaetoceros lorenzianus-infecting DNA virus; CdebDNAV: Chaetoceros debilis-infecting DNA virus; TnitDNAV: Thalassionema nitzschioides-infecting DNA virus; eGFP: enhanced green fluorescence protein; Sh ble: bleomycin-resistant gene.

In addition to DIVs, other viruses can help explore their genetic elements and design a novel viral-based vector, particularly those with ssDNA or dsRNA genomes. Among them, viral species infecting the most commonly studied microalgal, such as the genus *Chlorella*, may offer a useful genetic toolbox. For example, the *Paramecium bursaria Chlorella virus 1* (PBCV-1), a large dsDNA virus (>300 kb) infecting the green microalgae *Chlorella variabilis* NC64A, is now a model system for studying DNA virus/algal interactions, which has also been tested for biomass saccharification with subsequent bioethanol production and proteins involved in cell wall degradation [182–185]. Another virus fully sequenced that infects the *Chlorella* genus with potential biotechnology application are those that exclusively multiply in Syngen 2–3 or SAG 3.83 cells, which could lead to specific protein expression in microalgal strains. The prototype viruses are only Syngen viruses—NE5 (OSy-NE5) and *Acanthocystis turfacea* chlorella virus (ATCV-1) [186,187].

### 7. Challenges and Perspectives

In recent years, the current pandemic has pushed progress of several biomedical technologies, e.g., RNA vaccines and adenovirus-based vaccines. Based on these advances, what are the key insights from the field of algae-based biopharmaceuticals? Biopharmaceuticals using algae are considered a promising alternative for improving global health. Algae offer low production costs and some species are already used at industrial levels.
in the food industry and thus are considered safe for use as delivery vehicles, especially oral formulations. However, although the proof of concept for using algae to produce and even deliver biopharmaceutical has been reported by several groups, a number of challenges remain to be addressed in this field, including improving recombinant protein yield productivity.

Another critical path that deserves research attention in developing algae-made biopharmaceuticals is related to regulation. Defining the main guidelines for specific regulations applied to this type of biological agent is a major priority task. Performing clinical trials requires translating prototypes generated in academic labs to facilities with good laboratory practices that can approve and perform clinical trials. Moreover, implementing GMP-compliant processes in cooperation with pharmaceutical companies is urgently needed.

The current pandemic has increased support from several countries to invest in biomedical research and strengthen the developmental path for drugs and biologics. For example, several developing and emerging countries are increasing funding for research on innovative platforms for biopharmaceuticals production, including Thailand and Mèxico. We consider that the innovative green platforms required to produce biopharmaceuticals are a promising niche that could be accelerated by such initiatives. However, this should be a mid-term goal considering that conventional production systems with well-established regulatory frameworks will be the priority for such countries to provide rapid solutions for immediate needs. As biopharmaceuticals are inherently more complex than conventional chemical drugs, they demand a more complicated manufacturing process with varying quality and demands for extensive processes and product understanding. In addition, downstream processing represents another bottleneck. For algae, eliminating large amounts of lipids present in total extracts should be studied and the impact of differential glycosylation compared with mammalian glycosylation is another aspect that deserves attention.

Although the good manufacturing practice (GMP) standards of various regulatory authorities and international organizations are very similar and appropriate in addressing the manufacturing challenges, introducing innovative platforms always presents challenges. This challenge is exacerbated in developing or emerging countries that require affordable biopharmaceuticals. For instance, a recent study by Rahalkar et al. (2021) revealed that, in several emerging countries, the lack of standardized biosimilar development criteria and regulatory convergence across agencies led to challenges in multi-country biosimilar development, limiting our ability to introduce new, cheaper biosimilars into the market [188]. Unfortunately, for biopharmaceuticals produced in algae, this remains an ongoing challenge.

Although using viral vectors improves efficiency in expression systems, using Agrobacterium presents the need for complex purification steps to eliminate bacterial endotoxins. Therefore, expanding stable transformation systems to express viral replicons under an inducible approach is a possible solution to this limitation. Avoiding antibiotic-resistant markers is another challenge when designing vectors. Alternative markers, such as nutrient-selective markers, are accruing more interest. Another possibility is developing oral formulations subjected to less strict regulations. It is clear that this field is still in its infancy; thus, exploring new constructs optimized for model species, especially C. reinhardtii, are required. Special emphasis on developing vectors based on new algae viruses is crucial.

8. Concluding Remarks

Although using viral-based expression systems in algae is still new, this technology has immense potential to revolutionize the algae-based biopharmaceuticals field by offering higher yields and shorter production times compared with chloroplast and nuclear stable transformation methods. The following decade will be critical, as technology will benefit from refreshed interest when supporting biomedical research in response to the COVID-19 pandemic. Research and development goals should be focused not only on generating
prototypes in academic labs but also on critical regulatory issues to ensure the success of new products that enter the market and ultimately benefit human health, especially in developing and emerging countries. On February 2022, Medicago, a Canadian company, and GlaxoSmithKline (GSK) announced approval by the Health agency in Canada of COVIFENZ®, a COVID-19 vaccine produced in plants. This is a milestone, as it is the first vaccine produced using a green platform approved for human use. Will algae-based products reach the same success? The following decade will be crucial in addressing this goal.

Author Contributions: Conceptualization, S.V. and O.C.B.-M.; writing—original draft preparation, O.C.B.-M., G.M.; S.R.-M.; writing—review and editing, S.V.; O.C.B.-M.; S.R.-M.; supervision, S.V. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Chulalongkorn University (Grant No. ReinUni_65_03_33_18).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The author Omayra C. Bolaños-Martinez is an alumnus of the Second Century Fund (C2F) recipient, Chulalongkorn University.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. De Morais, M.G.; Vaz, B.D.S.; de Morais, E.G.; Costa, J.A.V. Biologically active metabolites synthesized by microalgae. Biomed. Res. Int. 2015, 2015, 835761. [CrossRef] [PubMed]
2. Grama, S.B.; Liu, Z.; Li, J. Emerging trends in genetic engineering of microalgae for commercial applications. Mar. Drugs 2022, 20, 285. [CrossRef] [PubMed]
3. Camacho, F.; Macedo, A.; Malcata, F. Potential industrial applications and commercialization of microalgae in the functional food and feed industries: A short review. Mar. Drugs 2019, 17, 312. [CrossRef] [PubMed]
4. Rasmussen, A.S.B.; Hammou, A.; Poulsen, T.F.; Laursen, M.C.; Hansen, S.F. Definition, categorization, and environmental risk assessment of biopharmaceuticals. Sci. Total Environ. 2021, 789, 147884. [CrossRef]
5. Mizukami, A.; Caron, A.L.; Picano-Castro, V.; Swiech, K. Platforms for recombinant therapeutic glycoprotein production. Methods Mol. Biol. 2018, 1674, 1–14. [CrossRef]
6. Baeshen, M.N.; Al-Hejin, A.M.; Bora, R.S.; Ahmed, M.M.; Ramadan, H.A.; Saini, K.S.; Baeshen, N.A.; Redwan, E.M. Production of biopharmaceuticals in E. coli: Current scenario and future perspectives. J. Microbiol. Biotechnol. 2015, 25, 953–962. [CrossRef]
7. Madhavan, A.; Arun, K.B.; Sindhu, R.; Krishnamoorthy, J.; Reshmy, R.; Sirohi, R.; Pugazhendi, A.; Awasthi, M.K.; Szakacs, G.; Binod, P. Customized yeast cell factories for biopharmaceuticals: From cell engineering to process scale up. Microb. Cell Fact. 2021, 20, 124. [CrossRef]
8. Hanisch, F.G. Recombinant norovirus capsid protein VP1 (GII.4) expressed in H5 insect cells exhibits post-translational modifications with potential impact on lectin activity and vaccine design. Glycobiology 2022, 32, 496–505. [CrossRef]
9. Rosales-Mendoza, S.; Solis-Andrade, K.I.; Márquez-Escobar, V.A.; González-Ortega, O.; Bañuelos-Hernandez, B. Current advances in the algae-made biopharmaceuticals field. Expert Opin. Biol. Ther. 2020, 20, 751–766. [CrossRef]
10. Khavari, F.; Saidijam, M.; Taheri, M.; Nouri, F. Microalgae: Therapeutic potentials and applications. Mol. Biol. Rep. 2021, 48, 4757–4765. [CrossRef]
11. Jareonsin, S.; Pumas, C. Advantages of heterotrophic microalgae as a host for phytochemicals production. Front. Bioeng. Biotechnol. 2021, 9, 628597. [CrossRef] [PubMed]
12. Gutierrez, S.; Lauersen, K.J. Gene delivery technologies with applications in microalgal genetic engineering. Biology 2021, 10, 265. [CrossRef] [PubMed]
13. Gong, Y.; Hu, H.; Gao, Y.; Xu, X.; Gao, H. Microalgae as platforms for production of recombinant proteins and valuable compounds: Progress and prospects. J. Ind. Microbiol. Biotechnol. 2011, 38, 1879–1890. [CrossRef] [PubMed]
14. Bafuelos-Hernández, B.; Beltrán-López, J.I.; Rosales-Mendoza, S. Production of biopharmaceuticals in microalgae. In Handbook of Marine Microalgae; Academic Press: Cambridge, MA, USA, 2015; pp. 281–298.
15. Doron, L.; Segal, N.; Shapiro, M. Transgene expression in microalgae from tools to applications. Front. Plant Sci. 2016, 7, 505. [CrossRef]
16. Sproles, A.E.; Fields, F.J.; Smalley, T.N.; Le, C.H.; Badary, A.; Mayfield, S.P. Recent advancements in the genetic engineering of microalgae. Algal Res. 2021, 53, 102158. [CrossRef]
17. Kseliková, V.; Singh, A.; Bialevich, V.; Čičková, M.; Bišová, K. Improving microalgae for biotechnology-From genetics to synthetic biology-Moving forward but not there yet. *Biotechnol. Adv.* 2022, 58, 107885. [CrossRef]

18. Kindle, K.L. High-frequency nuclear transformation of *Chlamydomonas reinhardtii*. *Proc. Natl. Acad. Sci. USA* 1990, 87, 1228–1232. [CrossRef]

19. Kindle, K.L.; Schnell, R.A.; Fernandez, E.; Lefebvre, P.A. Stable nuclear transformation of *Chlamydomonas* using the *Chlamydomonas* gene for nitrate reductase. *J. Cell Biol.* 1989, 109, 2589–2601. [CrossRef]

20. Shimogawara, K.; Fujiwara, S.; Grossman, A.; Usuda, H. High-efficiency transformation of *Chlamydomonas reinhardtii* by electroporation. *Genetics* 1998, 4, 1821–1828. [CrossRef]

21. Hwang, H.H.; Yu, M.; Lei, E.M. *Agrobacterium*-mediated plant transformation: Biology and applications. In *Arabidopsis Book*; American Society of Plant Biologists: Rockville, MD, USA, 2017; Volume 15, p. e0186.

22. Kathiresan, S.; Chandrashekar, A.; Ravishankar, G.A.; Sarada, R. *Agrobacterium*-mediated transformation in the green alga *Haematococcus pluvialis* (Chlorophyceae, Volvocales). *J. Physiol.* 2009, 45, 642–649. [CrossRef]

23. Kumar, S.V.; Misquitta, R.W.; Reddy, V.S.; Rao, B.J.; Rajam, M.V. Genetic transformation of the green alga *Chlamydomonas reinhardtii* by *Agrobacterium tumefaciens*. *Plant Sci.* 2004, 166, 731–738. [CrossRef]

24. Cui, Y.; Wang, J.; Jiang, P.; Bian, S.; Qin, S. Transformation of *Platymonas* (Tetraselmis) subcordiformis (Prasinophyceae, *Monoraphidium*) by *Agrobacterium tumefaciens*. *Plant Sci.* 2005, 169, 403–409. [CrossRef]

25. Wang, P.; Wang, G.; Teng, Y.; Li, X.; Xu, X.; Li, Y. Effects of cefotaxime and kanamycin on thallus proliferation and transformation of *Porphyra yezoensis* and their inhibition on *Agrobacterium tumefaciens*. *Mar. Biol. Res.* 2010, 6, 100–105. [CrossRef]

26. Sodeinde, O.A.; Kindle, K.L. Homologous recombination in the nuclear genome of *Chlamydomonas reinhardtii*. *Proc. Natl. Acad. Sci. USA* 1993, 90, 9199–9203. [PubMed]

27. Sreenikethanam, A.; Raj, S.; Banu, R.J.; Gugulothu, P.; Bajhiaiy, A.K. Genetic engineering of microalgae for secondary metabolite production: Recent developments, challenges, and future prospects. *Front. Bioeng. Biotechnol.* 2022, 10, 836056. [CrossRef]

28. Kindle, K.L.; Richards, K.L.; Stern, D.B. Engineering the chloroplast genome: Techniques and capabilities for chloroplast transformation in *Chlamydomonas reinhardtii*. *Proc. Natl. Acad. Sci. USA* 1991, 88, 1721–1725. [CrossRef]

29. Economou, C.; Wannathong, T.; Szaub, J.; Purton, S. A simple low-cost method for chloroplast transformation of the green alga *Chlamydomonas reinhardtii*. In *Methods in Molecular Biology*; Springer International Publishing: Cham, Switzerland, 2014; Volume 1132, pp. 401–411. [CrossRef]

30. Rochaix, J.D.; Surzycki, R.; Ramundo, S. Tools for regulated gene expression in the chloroplast of *Chlamydomonas*. In *Methods in Molecular Biology*; Springer International Publishing: Cham, Switzerland, 2014; Volume 1132, pp. 413–424. [CrossRef]

31. Jarvis, E.E.; Brown, I.M. Transient expression of firefly luciferase in protoplasts of the green alga *Chlorella ellipsoidea*. *Curr. Genet.* 1991, 19, 317–321. [CrossRef]

32. Wannathong, T.; Waterhouse, J.C.; Young, R.E.; Economou, C.K.; Purton, S. New tools for chloroplast genetic engineering allow the synthesis of human growth hormone in the green alga *Chlamydomonas reinhardtii*. *Appl. Microbiol. Biotechnol.* 2016, 100, 5467–5477. [CrossRef]

33. Rosenberg, J.N.; Oyler, G.A.; Wilkinson, L.; Betenbaugh, M.J. A green light for engineered algae: Redirecting metabolism to fuel a biotechnology revolution. *Curr. Opin. Biotechnol.* 2008, 19, 430–436. [CrossRef]

34. Barrera, D.J.; Mayfield, S.P. High-value recombinant protein production in microalgae. In *Methods in Molecular Biology*; Springer: Cham, Switzerland, 2021; Volume 2636, pp. 135–163. [CrossRef]

35. Malla, A.; Rosales-Mendoza, S.; Phoolcharoen, W.; Vimolmangkang, S. Efficient transient expression of recombinant proteins using DNA viral vectors in freshwater microalgal species. *Front. Plant Sci.* 2021, 12, 983. [CrossRef]

36. Feng, S.; Xue, L.; Liu, H.; Lu, P. Improvement of efficiency of genetic transformation for *Dunaliella salina* by glass beads method. *Mar. Biol. Res.* 2009, 36, 1433–1439. [CrossRef] [PubMed]

37. Cui, Y.; Wang, J.; Jiang, P.; Biao, S.; Qin, S. Transformation of Platymonas (Tetraselmis) subcordiformis (Prasinophyceae, *Chlorophyta*) by agitator with glass beads. *World J. Microbiol. Biotechnol.* 2010, 26, 1653–1657. [CrossRef]

38. Wang, L.; Yang, L.; Wen, X.; Chen, Z.; Liang, Q.; Li, J.; Wang, W. Rapid and high efficiency transformation of *Chlamydomonas reinhardtii* by square-wave electroporation. *Biocell.* 2019, 39, BS2R20181210. [CrossRef] [PubMed]

39. Im, D.J.; Jeong, S.N.; Yoo, B.S.; Kim, B.; Kim, D.P.; Jeong, W.J.; Kang, I.S. Digital microfluidic approach for efficient electroporation with high productivity: Transgene expression of microalgae without cell wall removal. *Anal. Chem.* 2015, 87, 6592–6599. [CrossRef] [PubMed]

40. Chen, Y.; Hu, H. High efficiency transformation by electroporation of the freshwater alga *Nannochloropsis* *limnetica* in freshwater microalgae. *Food Sci. Biotechnol.* 2013, 63, 61–68. [CrossRef]

41. Guo, S.L.; Zhao, X.Q.; Tang, Y.; Wen, C.; Alam, M.A.; Ho, S.H.; Bai, F.W.; Chang, J.S. Establishment of an efficient genetic transformation system in *Scenedesmus obticus*. *J. Biotechnol.* 2013, 163, 61–68. [CrossRef]

42. Jaeger, D.; Hübner, W.; Huser, T.; Mussgnug, J.H.; Kruse, O. Nuclear transformation and functional gene expression in the oleaginous microalga *Monoraphidium neglectum*. *J. Biotechnol.* 2017, 249, 10–15. [CrossRef]

43. Run, C.; Fang, L.; Fan, J.; Fan, C.; Luo, Y.; Hu, Z.; Li, Y. Stable nuclear transformation of the industrial alga *Chlorella pyrenoidosa*. *Algal Res.* 2016, 17, 196–201. [CrossRef]
45. Chen, H.L.; Li, S.S.; Huang, R.; Tsai, H.J. Conditional production of a functional fish growth hormone in the transgenic line of \textit{nannochloropsis oculata} (Eustigmatophyceae) 1. \textit{J. Phycol.} 2008, 44, 768–776. [CrossRef]  
46. Anula, N.; Chandrashekar, A.; Ravishankar, G.A.; Sarada, R. Establishment of \textit{Agrobacterium tumefaciens}-mediated genetic transformation in \textit{Dunaliella bardawil}. \textit{Eur. J. Phycol.} 2011, 46, 36–44. [CrossRef]  
47. Srinivasan, R.; Gothandam, K.M. Synergistic action of D-Glucose and acetosyringone on \textit{Agrobacterium} strains for efficient \textit{Dunaliella} transformation. \textit{PLoS ONE} 2016, 11, e0158322. [CrossRef] [PubMed]  
48. Schiedlmeier, B.; Schmitt, R.; Müller, W.; Kirk, M.M.; Gruber, H.; Mages, W.; Kirk, D.L. Nuclear transformation of \textit{Volvex carteri}. \textit{Proc. Natl. Acad. Sci. USA} 1994, 91, 5080–5084. [CrossRef] [PubMed]  
49. Boynton, J.E.; Gillham, N.W.; Harris, E.H.; Hosler, J.P.; Johnson, A.M.; Jones, A.R.; Randolph-Anderson, B.L.; Robertson, D.; Klein, T.M.; Shark, K.B.; et al. Chloroplast transformation in \textit{Chlamydomonas} with high velocity microprojectiles. \textit{Science} 1988, 240, 1534–1538. [CrossRef]  
50. Mini, P.; Demurtas, O.C.; Valentini, S.; Pallara, P.; Aprea, G.; Ferrante, P.; Giuliano, G. \textit{Agrobacterium}-mediated and electroporation mediated transformation of \textit{Chlamydomonas reinhardtii}: A comparative study. \textit{BMC Biotechnol.} 2018, 18, 11. [CrossRef]  
51. Gregory, J.A.; Topol, A.B.; Doerner, D.Z.; Mayfield, S. Alga-produced cholera toxin-Pf525 fusion proteins as oral vaccines. \textit{Appl. Environ. Microb.} 2013, 79, 3917–3925. [CrossRef]  
52. Hempel, F.; Maier, U.G. An engineered diatom acting like a plasma cell secreting human IgG antibodies with high efficiency. \textit{Microb. Cell Fact.} 2012, 11, 126. [CrossRef]  
53. Dunahay, T.G.; Jarvis, E.E.; Roessler, P.G. Genetic transformation of the diatoms \textit{Cyclotella cryptica} and \textit{Navicula saprophila}. \textit{J. Phycol.} 1995, 31, 1004–1012. [CrossRef]  
54. Fischer, H.; Robl, I.; Sumper, M.; Kröger, N. Targeting and covalent modification of cell wall and membrane proteins heterologously expressed in the diatom \textit{Cylindrotheca fusiformis} (Bacillariophyceae). \textit{J. Phycol.} 1999, 35, 113–120. [CrossRef]  
55. Dunahay, T.G. Transformation of \textit{Chlamydomonas reinhardtii} with silicon carbide whiskers. \textit{Biotechniques} 1993, 15, 452–455.  
56. Wang, K.; Drayton, P.; Frame, B.; Dunwell, J.; Thompson, J. Whisker mediated plant transformation an alternative technology. In \textit{In Vitro Cell Dev. Biol.} 1995, 31, 101–104. [CrossRef]  
57. Chai, X.J.; Chen, H.X.; Xu, W.Q.; Xu, Y.W. Expression of soybean Kunitz trypsin inhibitor gene SKTI in \textit{Dunaliella salina}. \textit{J. Appl. Phycol.} 2013, 25, 139–144. [CrossRef]  
58. Pratheesh, P.T.; Vineetha, M.; Kurup, G.M. An efficient protocol for the \textit{Agrobacterium}-mediated genetic transformation of microalga \textit{Chlamydomonas reinhardtii}. \textit{Mol. Biotechnol.} 2014, 56, 507–515. [CrossRef] [PubMed]  
59. Steinbrenner, J.; Sandmann, G. Transformation of the green alga \textit{Haematococcus pluvialis} with a phytoene desaturase for accelerated astaxanthin biosynthesis. \textit{Appl. Environ. Microb.} 2006, 72, 7477–7484. [CrossRef] [PubMed]  
60. Cha, T.S.; Yee, W.; Aziz, A. Assessment of factors affecting \textit{Agrobacterium}-mediated genetic transformation of the unicellular green alga, \textit{Chlorella vulgaris}. \textit{World J. Microbiol. Biotechnol.} 2012, 28, 1771–1779. [CrossRef]  
61. Rathod, J.P.; Prakash, G.; Pandit, R.; Lali, A.M. \textit{Agrobacterium}-mediated transformation of promising oil-bearing marine algae \textit{Parachlorella kessleri}. \textit{Photosynth. Res.} 2013, 118, 141–146. [CrossRef]  
62. Simon, D.P.; Anila, N.; Gayathri, K.; Sarada, R. Heterologous expression of β-carotene hydroxylase in \textit{Dunaliella salina} by \textit{Agrobacterium}–mediated genetic transformation. \textit{Algal Res.} 2016, 18, 257–265. [CrossRef]  
63. Khatiwada, B.; Kauto, L.; Sunna, A.; Sun, A.; Nevalainen, H. Nuclear transformation of the versatile microalga \textit{Euglena gracilis}. \textit{Algal Res.} 2019, 37, 178–185. [CrossRef]  
64. Dautor, Y.; Ubeda-Minguez, P.; Chlieh, T.; Garcia-Maroto, F.; Alonso, D.L. Development of genetic transformation methodologies for an industrially-promising microalga: \textit{Screednesmus almeriensis}. \textit{Biotechnol. Lett.} 2014, 36, 2551–2558. [CrossRef]  
65. Bashir, K.M.I.; Kim, M.-S.; Stahl, U.; Cho, M.-G. \textit{Agrobacterium} mediated genetic transformation of \textit{Dictyosphaerium pulchellum} for the expression of erythropoietin. \textit{J. Appl. Phycol.} 2018, 30, 3503–3518. [CrossRef]  
66. Rathod, J.P.; Gade, R.M.; Rathod, D.R.; Dudhare, M. A review on molecular tools of microalgal genetic transformation and their application for overexpression of different genes. \textit{Int. J. Curr. Microbiol. Appl. Sci.} 2017, 6, 3191–3207. [CrossRef]  
67. Brown, L.E.; Sprecher, S.L.; Keller, L.R. Introduction of exogenous DNA into \textit{Chlamydomonas reinhardtii} by electroporation. \textit{Mol. Cell Biol.} 1991, 11, 2328–2332. [CrossRef] [PubMed]  
68. Weaver, J.C. Plant Cell Electroporation and Electrofusion Protocols. In \textit{Methods in Molecular Biology}; Nickoloff, J.A., Ed.; Springer: Totowa, NJ, USA, 1995; Volume 55.  
69. Niu, Y.F.; Zhang, M.H.; Xie, W.H.; Li, J.N.; Gao, Y.F.; Yang, W.D.; Liu, J.S.; Li, H.Y. A new inducible expression system in a transformed green alga, \textit{Chlorella vulgaris}. \textit{Genet. Mol. Res.} 2011, 10, 3427–3434. [CrossRef] [PubMed]  
70. Liu, J.; Sun, Z.; Gerken, H.; Huang, J.; Jiang, Y.; Chen, F. Genetic engineering of the green alga \textit{Chlorella zofingiensis}: A modified norflurazon-resistant phytoene desaturase gene as a dominant selectable marker. \textit{Appl. Microbiol. Biotechnol.} 2014, 98, 5069–5079. [CrossRef] [PubMed]  
71. Liu, L.; Wang, Y.; Zhang, Y.; Chen, X.; Zhang, P.; Ma, S. Development of a new method for genetic transformation of the green alga \textit{Chlorella ellipsoidea}. \textit{Mol. Biotechnol.} 2013, 54, 211–219. [CrossRef] [PubMed]  
72. Yamano, T.; Fukuzawa, H. Transformation of the model microalga \textit{Chlamydomonas reinhardtii} without cell-wall removal. In \textit{Electroporation Protocols}; Li, S., Cutrer, J., Heller, R., Teissie, J., Eds.; Humana: New York, NY, USA, 2020. [CrossRef]  
73. Day, A.; Debuchy, R.; van Dillewijn, J.; Purton, S.; Rochaix, J.-D. Studies on the maintenance and expression of cloned DNA fragments in the nuclear genome of the green alga \textit{Chlamydomonas reinhardtii}. \textit{Physiol. Plant.} 1990, 78, 254–260. [CrossRef]
Remacle, C.; Cardol, P.; Coosemans, N.; Gaisne, M.; Bonnefoy, N. High-efficiency biotic transformation of Chlamydomonas mitochondria can be used to insert complex 1 genes. *Proc. Natl. Acad. Sci. USA* 2006, 103, 4771–4776. [CrossRef]

Jones, C.S.; Luong, T.; Hannon, M.; Tran, M.; Gregory, J.A.; Shen, Z.; Briggs, S.P.; Mayfield, S.P. Heterologous expression of the C terminal antigenic domain of the malaria vaccine candidate Pf48/45 in the green algae *Chlamydomonas reinhardtii*. *Appl. Microbiol. Biotechnol.* 2013, 97, 1987–1995. [CrossRef]

Dreesen, I.A.; Charpin-El Hamri, G.; Fussenegger, M. Heat-stable oral alga-based vaccine protects mice from *Staphylococcus aureus* infection. *J. Biotechnol.* 2010, 145, 273–280. [CrossRef]

Tan, C.; Qin, S.; Zhang, Q.; Jiang, P.; Zhao, F. Establishment of a micro-particle bombardment transformation system for *Dunaliella salina*. *J. Microbiol.* 2005, 43, 361–365.

Bayne, A.C.V.; Boltz, D.; Owen, C.; Betz, Y.; Maia, G.; Azadi, P.; Archer-Hartmann, S.; Zirkle, R.; Lippmeier, J.C. Vaccination against influenza with recombinant hemagglutinin expressed by Schizochytrium sp. confers protective immunity. *PLoS ONE* 2013, 8, e61790. [CrossRef] [PubMed]

Bañuelos-Hernández, B.; Monreal-Escalante, E.; González-Ortega, O.; Angulo, C.; Rosales-Mendoza, S. Algевич: An expression system for microalgae based on viral vectors. *Front. Microbiol.* 2017, 8, 1100. [CrossRef] [PubMed]

Baek, K.; Kim, D.H.; Jeong, J.; Sim, S.J.; Melis, A.; Kim, J.S.; Jin, E.; Bae, S. DNA-free two-gene knockout in *Chlamydomonas reinhardtii* via CRISPR-Cas9 ribonucleoproteins. *Sci. Rep.* 2016, 6, 30620. [CrossRef] [PubMed]

Shin, S.E.; Lim, J.M.; Koh, H.G.; Kim, E.K.; Kang, N.K.; Jeon, S.; Kwon, S.; Shin, W.S.; Lee, B.; Hwangbo, K.; et al. CRISPR/Cas9-induced knockdown and knock-inmutations in *Chlamydomonas reinhardtii*. *Sci. Rep.* 2016, 6, 27810. [CrossRef]

Serif, M.; Dubois, G.; Finoux, A.-L.; Teste, M.-A.; Jallet, D.; Daboussi, F. One-step generation of multiple gene knock-outs in the diatom *Phaeodactylum tricornutum* by DNA-free gene editing. *Nat. Commun.* 2018, 9, 3924. [CrossRef] [PubMed]

Chang, K.S.; Kim, J.; Park, H.; Hong, S.-J.; Lee, C.-G.; Jin, E. Enhanced lipid productivity in AGP knockout marine microalga *Tetraselmis sp.* using a DNA-free CRISPR/Cas9 RNP method. *Bioresour. Technol.* 2020, 303, 122932. [CrossRef]

Hawkins, R.L.; Nakamura, M. Expression of human growth hormone by the eukaryotic alga, *Chlorella*. *Curr. Microbiol.* 1999, 38, 335–341. [CrossRef]

Endo, H.; Yoshida, M.; Uji, T.; Saga, N.; Inoue, K.; Nagasawa, H. Stable nuclear transformation system for the coccilithophorid alga *Pleurochrysis carterae*. *Sci. Rep.* 2016, 6, 1–10. [CrossRef]

Karais, B.J.; Diner, R.E.; Lefebvre, S.C.; McQuaid, J.; Phillips, A.P.; Noddings, C.M.; Brunson, J.K.; Valas, R.E.; Deerinck, T.J.; Jablonski, J.; et al. Designer diatom epimemes delivered by bacterial conjugation. *Nat. Commun.* 2015, 6, 6925. [CrossRef]

Muñoz, C.F.; Sturme, M.H.J.; D’Adamo, S.; Weusthuis, R.A.; Wijffels, R.H. Stable transformation of the green algae *Apostichum obliquus* and *Neochloris oleoabundans* based on *E. coli* conjugation. *Algal Res.* 2019, 39, 101453. [CrossRef]

Zhou, X.; Zhang, X.; Boualavong, J.; Durney, A.R.; Wang, T.; Kirshner, S.; Wentz, M.; Mukaibo, H. Electrokinetically controlled fluid injection into unicellular microalgae. *Electrophoresis* 2017, 38, 2587–2591. [CrossRef] [PubMed]

Zhou, H.C.; Long, J.R.; Yagh, O.M. Introduction to metal-organic frameworks. *Chem. Rev.* 2012, 112, 673–674. [CrossRef]

Silva, S.; Almeida, A.J.; Vale, N. Combination of cell-penetrating peptides with nanoparticles for therapeutic application: A review. *Biomolecules* 2019, 9, 22. [CrossRef] [PubMed]

Lanigan, T.M.; Kopera, H.C.; Saunders, T.L. Principles of Genetic Engineering. *Genes* 2020, 11, 291. [CrossRef] [PubMed]

Radakovits, R.; Jinkerson, R.E.; Fuerstenberg, S.I.; Tae, H.; Settlage, R.E.; Boore, J.L.; Posewitz, M.C. Draft genome sequence and genetic transformation of the oleaginous alga *Nannochloropsis gaditana*. *Nat. Commun.* 2012, 3, 686. [CrossRef]

León-Bañares, R.; González-Ballesta, D.; Galván, A.; Fernández, E. Transgenic microalgae as green cell-factories. *Trends Biotechnol.* 2004, 22, 45–52. [CrossRef] [PubMed]

Potvin, G.; Zhang, Z. Strategies for high-level recombinant protein expression in transgenic microalgae: A review. *Biotechnol. Adv.* 2010, 28, 910–918. [CrossRef] [PubMed]

Lichtenthaler, H.K.; Schwender, J.; Disch, A.; Rohmer, M. Biosynthesis of isoprenoids in higher plant chloroplasts proceeds via a mevalonate-independent pathway. *FEBS Lett.* 1997, 400, 271–274. [CrossRef]

Bowsner, C.G.; Tobin, A.K. Compartmentation of metabolism within mitochondria and plastids. *J. Exp. Bot.* 2001, 52, 513–527. [CrossRef]

Gallaher, S.D.; Fitz-Gibbon, S.T.; Strenkert, D.; Purvine, S.O.; Pellegrini, M.; Merchant, S.S. High-throughput sequencing of the chloroplast and mitochondrion of *Chlamydomonas reinhardtii* to generate improved de novo assemblies, analyze expression patterns and transcript speciation, and evaluate diversity among laboratory strains and wild isolates. *Plant. J.* 2018, 93, 545–565. [CrossRef]

Kwon, Y.M.; Kim, K.W.; Choi, T.-Y.; Kim, S.Y.; Kim, J.Y.H. Manipulation of the microalgal chloroplast by genetic engineering for biotechnological utilization as a green biofactory. *World J. Microbiol. Biotechnol.* 2018, 34, 183. [CrossRef] [PubMed]

Sun, M.; Qian, K.; Su, N.; Chang, H.; Liu, J.; Shen, G. Foot-and-mouth disease virus VP1 protein fused with cholera toxin B subunit expressed in *Chlamydomonas reinhardtii* chloroplast. *Biotecnol. Lett.* 2003, 25, 1087–1092. [CrossRef] [PubMed]

Bertalan, I.; Munder, M.C.; Weiß, C.; Kopf, J.; Fischer, D.; Johanningmeier, U. A rapid, modular and marker-free chloroplast expression system for the green alga *Chlamydomonas reinhardtii*. *J. Biotechnol.* 2015, 195, 60–66. [CrossRef] [PubMed]

Xie, W.-H.; Zhu, C.-C.; Zhang, N.-S.; Li, D.-W.; Yang, W.-D.; Liu, J.-S.; Sathishkumar, R.; Li, H.Y. Construction of novel chloroplast expression vector and development of an efficient transformation system for the diatom *Phaeodactylum tricornutum*. *Mar. Biotechnol.* 2014, 16, 538–546. [CrossRef] [PubMed]
102. Fiehn, O. Metabolomics—The link between genotypes and phenotypes. *Plant Mol. Biol.* 2002, 48, 155–171. [CrossRef] [PubMed]

103. Senousy, H.H.; Abd Ellatif, S.; Ali, S. Assessment of the antioxidant and anticancer potential of different isolated strains of cyanobacteria and microalgae from soil and agriculture drain water. *Environ. Sci. Pollut. Res. Int.* 2020, 27, 18463–18474. [CrossRef] [PubMed]

104. Shanab, S.M.; Mostafa, S.S.; Shalaby, E.A.; Mahmoud, G.I. Aqueous extracts of microalgae exhibit antioxidant and anticancer activities. *Asian Pac. J. Trop. Biomed.* 2012, 2, 608–615. [CrossRef]

105. Suh, S.S.; Kim, S.M.; Kim, J.E.; Hong, J.M.; Lee, S.G.; Youn, U.J.; Han, S.J.; Kim, I.C.; Kim, S. Anticancer activities of ethanol extract from the Antarctic freshwater microalgae, *Botryocladus caseus* sp. *BMC Complement. Altern. Med.* 2017, 17, 509. [CrossRef]

106. Zaharieva, M.M.; Zheleva-Dimitrova, D.; Rusinova-Videva, S.; Ilieva, Y.; Brachkova, A.; Balabanova, V.; Grevnova, R.; Kim, T.C.; Kaleva, M.; Georgieva, A.; et al. Antimicrobial and antioxidant potential of *Scenedesmus obliquus* microalgae in the context of integral biorefinery concept. *Molecules* 2022, 27, 519. [CrossRef]

107. Hwang, J.; Yadav, D.; Lee, P.C.; Jin, J.O. Immunomodulatory effects of polysaccharides from marine algae for treating cancer, infectious disease, and inflammation. *Phytother. Res.* 2022, 36, 761–777. [CrossRef]

108. Mehariya, S.; Goswami, R.K.; Karthikeyan, O.P.; Verma, P. Microalgae for high-value products: A way towards green nutraceutical and pharmaceutical compounds. *Chemosphere* 2021, 280, 130553. [CrossRef] [PubMed]

109. Sarker, S.; Manna, M.S.; Bhowmick, T.K.; Gayen, K. Priority-based multiple products from microalgae: Review on techniques and strategies. *Crit. Rev. Biotechnol.* 2020, 40, 590–607. [CrossRef] [PubMed]

110. Castro, J.S.; Calijuri, M.L.; Ferreira, J.; Assemay, P.P.; Ribeiro, V.J. Microalgae based biofertilizer: A life cycle approach. *Sci. Total Environ.* 2020, 724, 138138. [CrossRef] [PubMed]

111. Lakatos, G.E.; Ranglová, K.; Manoel, J.C.; Grivalský, T.; Kopecký, J.; Mosojídek, J. Bioethanol production from microalgae polysaccharides. *Folia Microbiol.* 2019, 64, 627–644. [CrossRef] [PubMed]

112. Plöhn, M.; Spain, O.; Sirin, S.; Silva, M.; Escudero-Oñate, C.; Ferrando-Climent, L.; Allahverdiyeva, Y.; Funk, C. Wastewater treatment by microalgae. *Physiol. Plant.* 2021, 173, 568–578. [CrossRef] [PubMed]

113. Hom-Diaz, A.; Llorca, M.; Rodríguez-Mozaz, S.; Vicent, T.; Barceló, D.; Bánquez, P. Microalgae cultivation on wastewater digestate: β-estradiol and 17α-ethynylestradiol degradation and transformation products identification. *J. Environ. Manag.* 2015, 15, 106–113. [CrossRef] [PubMed]

114. Heimann, K.; Huerlimann, R. Microalgal classification: Major classes and genera of commercial microalgal species. In *Handbook of Marine Microalgae*; Kim, S.-K., Ed.; Academic Press: Busan, South Korea, 2015; pp. 25–41.

115. Márquez-Escobar, V.A.; Bañuelos-Hernández, B.; Rosales-Mendoza, S. Expression of a Zika virus antigen in microalgae: Towards mucosal vaccine development. *J. Biotechnol.* 2018, 282, 86–91. [CrossRef]

116. Castellanos-Huerta, I.; Bañuelos-Hernández, B.; Téllez, G.; Rosales-Mendoza, S.; Brieba, L.G.; Esquivel-Ramos, E.; Beltrán-López, J.I.; Velázquez, G.; Fernandez-Siurob, I. Recombinant Hemagglutinin of Avian Influenza Virus H5 expressed in the chloroplast of *Chlamydomonas reinhardtii* and evaluation of its immunogenicity in chickens. *Avian. Dis.* 2016, 60, 784–791. [CrossRef]

117. Demur, I.; Massa, S.; Ferrante, P.; Venuti, A.; Francioni, R.; Giuliano, G. A *Chlamydomonas*-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection. *PLoS ONE* 2013, 8, e61473. [CrossRef]

118. Barahimipour, R.; Neupert, J.; Bock, R. Efficient expression of nuclear transgenes in the green alga *Chlamydomonas*: Synthesis of an HIV antigen and development of a new selectable marker. *Plant Mol. Biol.* 2016, 90, 403–418. [CrossRef]

119. Davis, A.; Crum, L.T.; Hildebrand, M. Expression of *Histophilus somni* IbpA DR2 protective antigen in the diatom *Dunaliella salina* by *Agrobacterium tumefaciens* for the expression of the Hemagglutinin of Avian Influenza Virus H5. *Microorganisms* 2022, 10, 361. [CrossRef]

120. Hempel, F.; Maurer, M.; Brockmann, B.; Mayer, C.; Biedenkopf, N.; Kelterbaum, A.; Becker, S.; Maier, U.G. From hybridomas to a robust microalgal-based production platform: Molecular design of a diatom secreting monoclonal antibodies directed against the Hemagglutinin of Avian Influenza Virus H5. *Microb. Cell Fact.* 2017, 16, 131. [CrossRef] [PubMed]

121. Shamriz, S.; Ofoghi, H. Engineering the chloroplast of *Chlamydomonas reinhardtii* to express the recombinant PfCelTOS-II antigen-adjuvant fusion protein. *J. Biotechnol.* 2018, 266, 111–117. [CrossRef]

122. Kwon, K.C.; Lamb, A.; Fox, D.; Jegathese, S.J.P. An evaluation of microalgae as a recombinant protein oral delivery platform for fish using green fluorescent protein (GFP). *Fish Shellfish Immunol.* 2019, 87, 414–420. [CrossRef]
128. Feng, S.; Feng, W.; Zhao, L.; Gu, H.; Li, Q.; Shi, K.; Guo, S.; Zhang, N. Preparation of transgenic Dunaliella salina for immunization against white spot syndrome virus in crayfish. Arch. Virol. 2014, 159, 519–525. [CrossRef]

129. Yang, Z.; Chen, F.; Li, D.; Zhang, Z.; Liu, Y.; Zheng, D.; Wang, Y.; Shen, G. Expression of human soluble TRAIL in Chlamydomonas reinhardtii chloroplast. Chin. Sci. Bull. 2006, 51, 1703–1709. [CrossRef]

130. Soria-Guerra, R.E.; Ramírez-Alonso, J.I.; Ibáñez-Salazar, A.; Govea-Alonso, D.O.; Paz-Maldonado, L.M.; Bañuelos-Hernández, B.; Korban, S.S.; Rosales-Mendoza, S. Expression of an HBcAg-based antigen carrying angiotensin II in Chlamydomonas reinhardtii as a candidate hypertension vaccine. Plant Cell Tissue Organ Cult. 2014, 116, 133–139. [CrossRef]

131. El-Ayouty, Y.; El-Manawy, I.; Nasih, S.; Hamdy, E.; Kebeish, R. Engineering Chlamydomonas reinhardtii for expression of functionally active human interferon-α. Mol. Biotechnol. 2019, 61, 134–144. [CrossRef] [PubMed]

132. Kiataramgul, A.; Maneenin, S.; Purton, S.; Areechon, N.; Hirono, I.; Brocklehurst, T.W.; Unajak, S. An oral delivery system for controlling white spot syndrome virus infection in shrimp using transgenic microalgae. Aquaculture 2020, 521, 735022. [CrossRef]

133. Charoonnart, P.; Worakajit, N.; Zedler, J.; Meetam, M.; Robinson, C.; Saksmarprome, V. Generation of microalgae Chlamydomonas reinhardtii expressing shrimp antiviral dsRNA without supplementation of antibiotics. Sci. Rep. 2019, 9, 3164. [CrossRef] [PubMed]

134. Gregory, J.A.; Li, F.; Tomosada, L.M.; Cox, C.J.; Topol, A.B.; Vinetz, J.M.; Mayfield, S.P. Algae-produced Pfs25 elicits antibodies in mice immunized with an oral delivery system. Plant Biotechnol. J. 2017, 15, 321–332. [CrossRef]

135. Rasala, B.A.; Muto, M.; Lee, P.A.; Jager, M.; Cardoso, R.M.; Behnke, C.A.; Kirk, P.; Hokanson, C.A.; Crea, R.; Mendez, M.; et al. Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii. Plant Biotechnol. J. 2010, 8, 719–733. [CrossRef]

136. Baier, T.; Kros, D.; Feiner, R.C.; Lauersen, K.J.; Müller, K.M.; Kruse, O. Engineered fusion proteins for efficient protein secretion in microalgae. Acta Biochim. Biophy. Sin. 2015, 47, 7–19. [CrossRef]

137. Feng, S.; Feng, W.; Zhao, L.; Gu, H.; Li, Q.; Shi, K.; Guo, S.; Zhang, N. Preparation of transgenic Dunaliella salina for immunization against white spot syndrome virus in crayfish. Arch. Virol. 2014, 159, 519–525. [CrossRef]

138. Mar. Drugs 2022, 20, 434

19 of 21

139. Li, A.; Huang, R.; Wang, C.; Hu, Q.; Li, H.; Li, X. Expression of anti-lipopolysaccharide factor isoform 3 in Chlamydomonas reinhardtii showing high antimicrobial activity. Mar. Drugs 2021, 19, 239. [CrossRef]

140. Lima, S.; Webb, C.L.; Deery, E.; Robinson, C.; Zedler, J.A. Human intrinsic factor expression for bioavailable vitamin B12 enrichment in microalgae. Biology 2018, 7, 19. [CrossRef] [PubMed]

141. Hempel, F.; Lau, J.; Klingl, A.; Maier, U.G. Algae as protein factories: Expression of a human antibody and the respective antigen in the green alga Chlamydomonas reinhardtii expressing shrimp antiviral dsRNA without supplementation of antibiotics. Sci. Rep. 2019, 9, 3164. [CrossRef] [PubMed]

142. Charoonnart, P.; Worakajit, N.; Zedler, J.; Meetam, M.; Robinson, C.; Saksmarprome, V. Generation of microalgae Chlamydomonas reinhardtii expressing shrimp antiviral dsRNA without supplementation of antibiotics. Sci. Rep. 2019, 9, 3164. [CrossRef] [PubMed]

143. Gregory, J.A.; Li, F.; Tomosada, L.M.; Cox, C.J.; Topol, A.B.; Vinetz, J.M.; Mayfield, S.P. Algae-produced Pfs25 elicits antibodies in mice immunized with an oral delivery system. Plant Biotechnol. J. 2017, 15, 321–332. [CrossRef]

144. Baier, T.; Kros, D.; Feiner, R.C.; Lauersen, K.J.; Müller, K.M.; Kruse, O. Engineered fusion proteins for efficient protein secretion in microalgae. Acta Biochim. Biophy. Sin. 2015, 47, 7–19. [CrossRef]

145. Rasala, B.A.; Muto, M.; Lee, P.A.; Jager, M.; Cardoso, R.M.; Behnke, C.A.; Kirk, P.; Hokanson, C.A.; Crea, R.; Mendez, M.; et al. Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii. Plant Biotechnol. J. 2010, 8, 719–733. [CrossRef]

146. Baier, T.; Kros, D.; Feiner, R.C.; Lauersen, K.J.; Müller, K.M.; Kruse, O. Engineered fusion proteins for efficient protein secretion in microalgae. Acta Biochim. Biophy. Sin. 2015, 47, 7–19. [CrossRef] [PubMed]

147. Hemple, F.; Lau, J.; Klingl, A.; Maier, U.G. Algae as protein factories: Expression of a human antibody and the respective antigen in the green alga Chlamydomonas reinhardtii expressing shrimp antiviral dsRNA without supplementation of antibiotics. Sci. Rep. 2019, 9, 3164. [CrossRef] [PubMed]

148. Baier, T.; Kros, D.; Feiner, R.C.; Lauersen, K.J.; Müller, K.M.; Kruse, O. Engineered fusion proteins for efficient protein secretion in microalgae. Acta Biochim. Biophy. Sin. 2015, 47, 7–19. [CrossRef] [PubMed]

149. Rasala, B.A.; Muto, M.; Lee, P.A.; Jager, M.; Cardoso, R.M.; Behnke, C.A.; Kirk, P.; Hokanson, C.A.; Crea, R.; Mendez, M.; et al. Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii. Plant Biotechnol. J. 2010, 8, 719–733. [CrossRef]

150. Fa, M.; Accossato, S.; Cella, R.; Fontana, F.; Goldschmidt-Clermont, M.; Leelavathi, S.; Reddy, V.S.; Longoni, P. Comparison of transplastomic Chlamydomonas reinhardtii and Nicotiana tabacum expression system for the production of a bacterial endoglucanase. Appl. Microbiol. Biotechnol. 2017, 101, 4085–4092. [CrossRef]

151. Kumar, A.; Falcao, V.R.; Sayre, R.T. Evaluating nuclear transgene expression systems in Chlamydomonas reinhardtii. Algal Res. 2013, 2, 321–332. [CrossRef]
152. Dong, B.; Cheng, R.Q.; Liu, Q.Y.; Wang, J.; Fan, Z.C. Multimer of the antimicrobial peptide Mytichitin-A expressed in Chlamydomonas reinhardtii exerts a broader antibacterial spectrum and increased potency. *J. Biosci. Bioeng.* 2018, 125, 175–179. [CrossRef] [PubMed]

153. Xue, B.; Dong, C.M.; Hu, H.H.; Dong, B.; Fan, Z.C. *Chlamydomonas reinhardtii*-expressed multimer of ToAMP4 inhibits the growth of bacteria of both Gram-positive and Gram-negative. *Process Biochem.* 2020, 91, 311–318. [CrossRef]

154. Pang, X.; Tong, Y.; Xue, W.; Yang, Y.F.; Chen, X.; Liu, J.; Chen, D. Expression and characterization of recombinant human lactoferrin in edible alga *Chlamydomonas reinhardtii*. *Biosci. Biotechnol. Biochem.* 2019, 83, 851–859. [CrossRef] [PubMed]

155. Hernández-Ramírez, J.; Wong-Arce, A.; González-Ortega, O.; Rosales-Mendoza, S. Expression in algae of a chimeric protein carrying several epitopes from tumor associated antigens. *Int. J. Biol. Macromol.* 2020, 147, 46–52. [CrossRef] [PubMed]

156. Ortega-Berlanga, B.; Bañuelos-Hernández, B.; Rosales-Mendoza, S. Efficient expression of an Alzheimer’s disease vaccine candidate in the microalga Schizochytrium sp. using the Algevir system. *Mol. Biotechnol.* 2018, 60, 362–368. [CrossRef]

157. He, Y.; Peng, H.; Liu, J.; Chen, F.; Zhou, Y.; Ma, X.; Chen, H.; Wang, K. Chlorella sp. transgenic with Scy-hepc enhancing the survival of Sparus macrocephalus and hybrid grouper challenged with Aeromonas hydrophila. *Fish Shellfish Immunol.* 2018, 73, 22–29. [CrossRef]

158. Georgianna, D.R.; Hannon, M.J.; Marcuschi, M.; Wu, S.; Botsch, K.; Lewis, A.J.; Hyun, J.; Mendez, M.; Mayfield, S.P. Production of recombinant enzymes in the marine alga Dunaliella tertiolecta. *Algal Res.* 2013, 2, 2–9. [CrossRef]

159. Wang, K.; Cui, Y.; Wang, Y.; Gao, Z.; Liu, T.; Meng, C.; Qin, S. Chloroplast genetic engineering of a unicellular green alga *Haematococcus pluvialis* plus expression of an anti-bacterial peptide. *Mar. Biotechnol.* 2020, 22, 572–580. [CrossRef] [PubMed]

160. Mardanova, E.S.; Blokhina, E.A.; Tsybalova, L.M.; Peyret, H.; Lomonossoff, G.P.; Ravin, N.V. Efficient transient expression of recombinant proteins in plants by the novel pEff vector based on the genome of Potato Virus X. *Front. Plant Sci.* 2017, 28, 247. [CrossRef] [PubMed]

161. Vidyasagar, P.; Sridive, V.N.; Rajan, S.; Praveen, A.; Srikanth, A.; Abhinay, G.; Siva Kumar, V.; Verma, R.R.; Rajendra, L. Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs. *Eur. J. Microbiol. Immunol.* 2014, 4, 56–64. [CrossRef]

162. Van Doremalen, N.; Lambe, T.; Spencer, A.; Belij-Rammerstorfer, S.; Purushotham, J.N.; Port, J.R.; Avanzato, V.A.; Bushmaker, T.; Flaxman, A.; Ulaszewksa, M.; et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. *Nature* 2020, 586, 578–582. [CrossRef]

163. D’Adamo, S.; Kormelink, R.; Martens, D.; Barbosa, M.J.; Wijffels, R.H. Rapid, high-level expression of glycosylated rice alpha-amylase in *Nicotiana benthamiana* using a rapid transient expression system. *Front. Plant Sci.* 2012, 5, 107790. [CrossRef]

164. McCormick, A.A.; Reinl, S.J.; Cameron, T.I.; Vojdani, F.; Fronefield, M.; Levy, R.; Tuse, D. Individualized human scFv vaccines and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs. *Vaccine* 2000, 19, 3356–3364. [CrossRef] [PubMed]

165. Kumagai, M.H.; Donson, J.; della-Cioppa, G.; Grill, L.K. Prospects for viruses infecting eukaryotic microalgae in biotechnology. *Biotechnol. Adv.* 2003, 21, 6–14. [CrossRef]

166. Ryabov, E.V.; Robinson, D.J.; Taliansky, M.E. A plant virus-encoded protein facilitates long-distance movement of heterologous viral RNA. *Proc. Natl. Acad. Sci. USA* 1999, 96, 1212–1217. [CrossRef]

167. Gleba, Y.; Klimyuk, V.; Marillonnet, S. Magnifection—a new platform for expressing recombinant vaccines in plants. *Annu. Rev. Phytopathol.* 2005, 43, 43–60. [CrossRef]

168. Salazar-Gonzalez, J.A.; Rosales-Mendoza, S.; Bañuelos-Hernández, B. Viral vector-based expression strategies. In *Genetically Engineered Plants as a Source of Vaccines against Wide Spread Diseases*; Rosales-Mendoza, S., Ed.; Springer: New York, NY, USA, 2014; pp. 43–60. [CrossRef]

169. Naseri, Z.; Ghaffar, K.; Seyed Javad, M.; Hamideh, O. Virus-based vectors: A new approach for the production of recombinant proteins. *J. Appl. Biotechnol. Rep.* 2019, 6, 6–14. [CrossRef]

170. Manley, B.; Bejarano, E.R.; Robertson, D.; Mansoor, S. Geminiviruses: Masters at redirecting and reprogramming plant processes. *Nat. Rev. Microbiol.* 2013, 11, 777–788. [CrossRef]

171. Rojas, M.R.; Macedo, M.A.; Maliano, M.R.; Soto-Aguilar, M.; Souza, J.O.; Briddon, R.W.; Kenyon, L.; Rivera Bustamante, R.F.; Rojas, M.R.; Macedo, M.A.; Maliano, M.R.; Soto-Aguilar, M.; Souza, J.O.; Briddon, R.W.; Kenyon, L.; Rivera Bustamante, R.F. World management of geminiviruses. *Annu. Rev. Phytopathol.* 2021, 59, 231–254. [CrossRef]

172. Zerbini, F.M.; Adkins, S.; et al. World management of geminiviruses. *Annu. Rev. Phytopathol.* 2021, 59, 231–254. [CrossRef]

173. Jiang, Y.; Yang, Y.; et al. World management of geminiviruses. *Annu. Rev. Phytopathol.* 2021, 59, 231–254. [CrossRef]

174. Okafor, C.C.; Kudirka, D.L.; et al. World management of geminiviruses. *Annu. Rev. Phytopathol.* 2021, 59, 231–254. [CrossRef]

175. Nicotiana benthamiana. *Mol. Biotechnol.* 2018, 60, 362–368. [CrossRef] [PubMed]

176. Phakhham, T.; Bulaon, C.J.; Khorattanakulchai, N.; Shanmugaraj, B.; Buranapraditkun, S.; Boonkrai, C.; Sooksai, S.; Hirankarn, N.; Abe, Y.; Strasser, R.; et al. Functional characterization of pembrolizumab produced in *Nicotiana benthamiana* using a rapid transient expression system. *Front. Plant Sci.* 2021, 12, 756299. [CrossRef] [PubMed]

177. Moon, K.B.; Jeon, J.H.; Choi, H.; Park, J.S.; Park, S.J.; Lee, H.J.; Park, J.M.; Cho, H.S.; Moon, J.S.; Oh, H.; et al. Construction of SARS-CoV-2 virus-like particles in plant. *Sci. Rep.* 2022, 12, 1005. [CrossRef] [PubMed]

178. Berntd, A.J.; Smalley, T.N.; Ren, B.; Simkovsky, R.; Badary, A.; Sproles, A.E.; Fields, F.J.; Torres-Tijj, Y.; Heredia, V.; Mayfield, S.P. Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae *Chlamydomonas reinhardtii*. *PLoS ONE* 2021, 16, e0257089. [CrossRef]
176. Gimpel, J.A.; Hyun, J.S.; Schoepp, N.G.; Mayfield, S.P. Production of recombinant proteins in microalgae at pilot greenhouse scale. *Biotechnol. Bioeng.* 2015, 112, 339–345. [CrossRef]

177. Zhao, Z.; Anselmo, A.C.; Mitragotri, S. Viral vector-based gene therapies in the clinic. *Bioeng. Transl. Med.* 2021, 7, e10258. [CrossRef]

178. Short, S.M.; Staniewski, M.A.; Chaban, Y.V.; Long, A.M.; Wang, D. Diversity of viruses infecting eukaryotic algae. *Curr. Issues Mol. Biol.* 2020, 39, 29–62. [CrossRef]

179. Coy, S.R.; Gann, E.R.; Pound, H.L.; Short, S.M.; Wilhelm, S.W. Viruses of eukaryotic algae: Diversity, methods for detection, and future directions. *Viruses* 2018, 10, 487. [CrossRef]

180. Sandaa, R.A.; Saltvedt, M.R.; Dahle, H.; Wang, H.; Våge, S.; Blanc-Mathieu, R.; Steen, I.H.; Grimsley, N.; Edvardsen, B.; Ogata, H.; et al. Adaptive evolution of viruses infecting marine microalgae (haptophytes), from acute infections to stable coexistence. *Biol. Rev. Camb. Philos. Soc.* 2022, 97, 179–194. [CrossRef] [PubMed]

181. Kadono, T.; Miyagawa-Yamaguchi, A.; Kira, N.; Tomaru, Y.; Okami, T.; Yoshimatsu, T.; Hou, L.; Ohama, T.; Fukunaga, K.; Okauchi, M.; et al. Characterization of marine diatom-infecting virus promoters in the model diatom *Phaeodactylum tricornutum*. *Sci. Rep.* 2015, 5, 18708. [CrossRef] [PubMed]

182. Blanc, G.; Duncan, G.; Agarkova, I.; Borodovsky, M.; Gurnon, J.; Kuo, A.; Lindquist, E.; Lucas, S.; Pangilinan, J.; Polle, J.; et al. The *Chlorella variabilis* NC64A genome reveals adaptation to photosymbiosis, coevolution with viruses, and cryptic sex. *Plant Cell.* 2010, 22, 2943–2955. [CrossRef] [PubMed]

183. Jeanniard, A.; Dunigan, D.D.; Gurnon, J.R.; Agarkova, I.V.; Kang, M.; Vitek, J.; Duncan, G.; McClung, O.W.; Larsen, M.; Claverie, J.M.; et al. Towards defining the chloroviruses: A genomic journey through a genus of large DNA viruses. *BMC Genom.* 2013, 14, 158. [CrossRef] [PubMed]

184. Cheng, Y.S.; Zheng, Y.; Labavitch, J.M.; VanderGheynst, J.S. Virus infection of *Chlorella variabilis* and enzymatic saccharification of algal biomass for bioethanol production. *Bioresour. Technol.* 2013, 137, 326–331. [CrossRef]

185. Agarkova, I.V.; Lane, L.C.; Dunigan, D.D.; Quispe, C.F.; Duncan, G.A.; Milrot, E.; Minsky, A.; Ghosh, J.S.; Van Etten, J.L. Identification of a Chlorovirus PBCV-1 protein involved in degrading the host cell wall during virus infection. *Viruses* 2017, 9, 13, 782. [CrossRef]

186. Quispe, C.F.; Ghosh, J.S.; Sonderman, O.; McQuinn, M.; Agarkova, I.; Battah, M.; Duncan, G.A.; Dunigan, D.D.; Smith, T.; De Castro, C.; et al. Characterization of a new chlorovirus type with permissive and non-permissive features on phylogenetically related algal strains. *Virology* 2017, 500, 103–113. [CrossRef]

187. Fitzgerald, L.A.; Graves, M.V.; Li, X.; Hartigan, J.; Pfützner, A.J.; Hoffart, E.; Van Etten, J.L. Sequence and annotation of the 288-kb ATCV-1 virus that infects an endosymbiotic chlorella strain of the heliozoon *Acanthocystis turfacea*. *Virology* 2007, 362, 350–361. [CrossRef]

188. Rahalkar, H.; Sheppard, A.; Lopez-Morales, C.A.; Lobo, L.; Salek, S. Challenges faced by the biopharmaceutical industry in the development and marketing authorization of biosimilar medicines in BRICS-TM countries: An exploratory study. *Pharmaceut. Med.* 2021, 35, 235–251. [CrossRef]